By Stephen Nakrosis 
 

Shares of pharmaceutical company Bristol-Myers Squibb Co. (BMY) are falling in Wednesday's late trading session after the company said a trial evaluating Opdivo plus chemotherapy in certain cancer patients didn't meet its pre-specified primary endpoint.

At 5:04 p.m. EDT, Bristol-Myers Squibb shares had lost 4.7% to trade at $41.20. After-hours volume topped 357,000 shares.

The company's shares closed the day's regular trading session with a 0.42% gain at $43.23.

After the bell, the company said Part 1a of the Phase 3 CheckMate -227 trial evaluating Opdivo, or nivolumab, with low-dose Yervoy, or ipilimumab, in certain cancer patients met the co-primary endpoint of overall survival.

Part 2 of the CheckMate -227 trial, evaluating Opdivo plus chemotherapy, didn't meet the pre-specified primary endpoint.

The company also said the time for its second-quarter earnings call has been rescheduled to 8:30 a.m. EDT on July 25.

 

Write to Stephen Nakrosis at stephen.nakrosis@wsj.com

 

(END) Dow Jones Newswires

July 24, 2019 17:30 ET (21:30 GMT)

Copyright (c) 2019 Dow Jones & Company, Inc.
Bristol Myers Squibb (NYSE:BMY)
Historical Stock Chart
Von Feb 2024 bis Mär 2024 Click Here for more Bristol Myers Squibb Charts.
Bristol Myers Squibb (NYSE:BMY)
Historical Stock Chart
Von Mär 2023 bis Mär 2024 Click Here for more Bristol Myers Squibb Charts.